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Colorectal cancer is one of the most common malignancies and a leading cause of cancer death worldwide. Molecular markers
may improve clinicopathologic staging and provide a basis to guide novel therapeutic strategies which target specific tumour-
associated molecules according to individual tumour biology; however, so far, no ideal molecular marker has been found to
predict disease progression. We tested Ki-67 proliferation marker in primary and lymph node metastasis of CRC. We observed a
statistical significant difference between the positive rates of neoplastic cells positively stained byKi-67 in both sites, with remarkable
increased number of Ki-67 positive cells in primary tumor cells compared to cancer cells that invaded lymph nodes. We can
speculate that the metastatic CRC in lymph node can be more resistant to the drugs that target cellular division.
1. Introduction
Colorectal cancer (CRC) is one of the most common malig-
nancies and a leading cause of cancer death worldwide [1–5].
European countries rank the highest in the global statistics, in
terms of both CRC incidence and mortality [4, 6], although
in recent years, a decline in CRC mortality rates has been
observed,mostly due to improvement in earlier diagnosis and
treatment [4, 7].
In Portugal, official data revealed that CRC is the second
most common type of cancer, in bothmen andwomen, and in
2008 it was responsible for 18.7% and 15.1%, respectively, of all
cancer in Portugal [8]. Regarding mortality, unlike European
data [9], there was an average increase of 3% from 2000 to
2005 [10] and in 2012 incidence andmortality rates are higher
than European rates [11].
For CRC, the pathologic clinical stage is currently the
single most important prognostic factor [1–4, 12, 13], corre-
lating with long-term survival [4, 14–17], although it does not
fully predict individual clinical outcome [4, 17–19]. This is
particularly true for those tumours with intermediate stage
disease (T3-T4N0M0) [19], where one-third of patients with
tumour-free lymph nodes have recurrences, and therefore
adjuvant chemotherapy may be beneficial [20]. In this group,
carcinoma cells are not detected in lymph nodes by con-
ventional staging methods in 24% of patients. So, lymphatic
staging is essential to improve treatment of these patients,
indeed one-third of the patients submitted to curative intent
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surgery die of local and/or distant tumour recurrence [4, 15].
Abdominal lymph nodes (38%) are the secondmost frequent
site of metastasis (38%), just after liver, that is, the organmost
frequently involved (38–60% of cases) and followed by lung
(38%) and peritoneum (28%) [4, 13].
A common feature of all cancers is the imbalance that
exists between the proliferative activity and cell death; there-
fore, the evaluation of cell proliferation rate may be interest-
ing in the study and characterization of tumours [21]. Some
molecules, such as the Ki-67 protein, permit this assessment
and are used as markers of proliferation because Ki67 expres-
sion is dependent of cell division rate; thus, overexpression of
these markers may suggest a disruption in the proliferation
mechanism leading to the appearance of tumours [21].
Ki-67 protein, when used to evaluate the percentage
of dividing cells, allows us to determine neoplastic growth
[21] and has been documented to correlate with neoplas-
tic progression [22] showing different levels of expression
between normal mucosa, adenoma, and adenocarcinoma
[23], verifying a progressive increasing of positive Ki-67
expression from the first (normal mucosa) to the last part of
the tissue (adenocarcinoma) [22, 24, 25].
Other studies correlate Ki-67 with the degree of malig-
nancy, tumour invasiveness [25, 26], metastatic potential
[21], patient survival, and the risk of relapse [27, 28]. Thus,
a high Ki-67 expression in tumour cells is assumed to
correlate with a poor tumour differentiation [24, 26] and an
increased infiltration of the bowel wall (pT) [26]. Micev et al.
[29] demonstrated that there is an association between Ki-67
expression and a less effective response in patients undergo-
ing chemotherapy.
Other correlations with clinical and pathological data
were also investigated and a correlationwas detected between
a high expression of this protein and the following variables:
patient’s age [25], tumour size [30], tumour localization [28],
dysplasia degree [30], the presence of lymph node metastasis
[22, 25, 28], and TNM [25] and Dukes [28] classification.
Thus, the younger is the patient, the greater is the cellular
proliferation and the lower is the degree of differentiation;
with increasingmalignancy a increased frequency of invasion
and metastasis are observed and thus poorer prognosis [25].
In CRC, the analysis of colon adenomas has shown a
different pattern for Ki-67 expression between normal tissue,
adenomas, and adenocarcinomas, being limited to the crypts
in normal tissue and expressed both in the crypts and in the
surface epithelium in adenomatous polyps (tubular, villous)
[31] and distributed homogeneously in adenocarcinoma [32].
Nussrat et al. [30] also observed an increase in Ki-67 rates
being associated with the growth and rise of dysplasia in
adenomas.
Studies on CRC indicated Ki-67 as a prognostic marker
as the survival rate for patients with high expression of Ki-67
is significantly lower compared to those with low expression
[25, 33–35] and a predictor of CRC recurrence [36]. Also sig-
nificant associations were found between higher index of Ki-
67 and increased tumour penetration [35, 37], the presence
of lymph node [22, 35] and distant [35] metastasis, advanced
TNM stage [32, 35], highest degree of differentiation, and
subtypes of adenocarcinoma other than mucinous [38].
However, not all studies are in agreement, and no correla-
tionswere observedwith patient age, gender, tumour location
[22, 30, 33, 39], and the type of adenoma [30] for some
of them. Allegra et al. [40] described inverse associations,
with a lower rate of Ki-67 to be associated with greater
recurrence and worse overall survival and Jansson and Sun
[39] did not find any associations between index Ki-67 and
clinicopathological data or prognosis.
Regarding the use of Ki-67 in CRC lymph node metas-
tasis, no information is available, and the only similar
study found compares Ki-67 index in primary tumour with
peritoneal metastasis and had observed a lower proliferative
index in metastasis compared with the primary tumour
[41]. However, in other types of cancer, in particular breast
cancer, a higher Ki-67 index was found in lymph node
metastasis than in primary tumours [42–44], suggesting
greater aggressiveness of these [42] and that the use of Ki-67
in lymph node metastasis may be important in selecting the
appropriate treatment for certain subgroups of patients [45].
Therefore, given the limited information concerning Ki-
67 index in CRC lymph nodes metastasis and primary
tumour, this study becomes relevant to determine Ki-67
index in the primary tumour and, respectively, lymph nodes
metastasis whilst trying to establish correlations with this and
clinicopathological data and the patient’s prognosis.
2. Materials and Methods
2.1. CRC Tumour Series. Tissue samples and data from 672
patients treated in Hospital de Braga, Portugal, between
January 1, 2005, and January 1, 2010, with CRC diagnosis were
collected prospectively. Tumour localization was recorded
and classified as colon and rectum (between anal verge and
15 cm at rigid rectoscopy).
The histological type of CRC was classified by two
experienced pathologists and tumour staging was graded
according to theTNMclassification, sixth edition [46]. Tissue
microarrays (TMAs) were constructed with the CRC series
of formalin-fixed, paraffin-embedded tissues and analyzed
by immunohistochemistry. Prior to tumour construction,
hematoxylin and eosin sections were reviewed to select
representative areas of the tumour and normal-adjacent
tissue. Each case was represented in the TMA by at least two
cores of 0.6mm.
2.2. Lymph Node Metastasis Series. From the same series of
colorectal cancer, patients with the diagnosis of CRC lymph
nodemetastasis were selected and a series of 210 patients were
also collected.
Additionally, 35 patients, with the diagnosis of CRC but
without lymph nodemetastasis, were also selected for control
of protein lymph node expression (stages T1 and T2/N0).
TMAs were constructed with the lymph node metastasis
series of formalin-fixed, paraffin-embedded tissues and ana-
lyzed by immunohistochemistry. Each case was represented
in the TMA by at least two cores of 0.6mm.
The study protocol was approved by the Ethics Commit-
tee of Hospital de Braga and ICVS.
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Figure 1: Immunohistochemical expression of Ki-67 in samples of skin: (a) original magnification ×40; (b) original magnification ×100; (c)
original magnification ×200.
Table 1: Detailed aspects of the immunohistochemical procedure used to visualise the Ki-67.
Protein marker Antigen retrieval Peroxidaseinactivation Detection system
Antibody
Company Dilution Incubation period
Ki-67 Citrate Buffer0.01M pH = 6.0
3% H2O2 in
methanol, 10min.
RTU Vectastain
ABC elite Reagent GenNova 1 : 200 Overnight
2.3. Immunohistochemistry. CRC and lymph nodes TMAs
protein expression was evaluated by immunohistochemistry.
Detailed information is given in Table 1. After the immuno-
histochemical procedure, the slides were evaluated and then
photographed under a microscope.
For positive control of the expression of Ki-67 a sample of
the skin was used (Figure 1).
2.4. Immunohistochemical Evaluation. The percentage of
immunoreactive cells was determined (which was named the
Ki-67 index), counting a total of 100 cells per section at ×20
magnification, and each one was assigned a score from 0 to 3,
as previously described by Pinheiro et al. [47].
Immunoreaction final score was defined as the sum of
both parameters and grouped as negative (0-1) and positive
(≥2). Evaluation of protein expression was performed by
blind analysis by two observers and discordant cases were
discussed in a double-headmicroscope in order to determine
a final score.
2.5. Statistical Analysis. All data were analyzed using the
Statistical Package for the Social Sciences, version 19.0 (SPSS
Inc., Chicago, IL, USA). All comparisons were examined for
statistical significance using Pearson’s chi-square (𝜒2) test and
Fisher’s exact test (when 𝑛 < 5), with the threshold for signif-
icance 𝑃 < 0.05. Survival curves were determined for overall
survival by the Kaplan-Meier method and log-rank test.
Expression differences between lymph node metastasis
and primary CRC were tested with McNemar test, with the
threshold for significance 𝑃 < 0.05.
3. Results
3.1. Ki-67 Expressions in CRC Samples. A total of 672 samples
were organized into TMAs, including tumour and normal
adjacent epithelium (NAE). Sections were evaluated for
immunoexpression and the obtained results are given in
Table 2, which summarizes the frequency of Ki-67 expression
in tumour cells and NAE.
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Table 2: Pattern of protein staining in tumour versus normal
adjacent epithelium.
Protein marker Immunoreaction
Ki-67 𝑛 Positive 𝑛 (%) 𝑃
CCR
NAE 140 34 (24.3)
<0.001
Tumour 506 345 (68.2)
Lymph node
Normal 2 2 (100.0) 0.502∗
Metastasis 109 60 (55.0)
NAE: normal adjacent epithelium; 𝑛: total number of cases with and without
expression of Ki-67; positive 𝑛 (%): total number of cases with expression of
Ki-67 and respective percentage.
∗Comparisons were examined for statistical significance using Fisher’s exact
test (when 𝑛 < 5).
We observed that 68.2% (𝑛 = 345) of the samples of
tumour tissue were positive for Ki-67, as compared to 24.3%
(𝑛 = 34) of samples of the samples of NAE. Thus, it was
concluded that the Ki-67 expression is significantly higher in
tumour tissue (𝑃 < 0.05), such as is shown in Table 2.
Figure 2 shows representative cases of positive staining
for Ki-67 in tumour cells and in NAE.
3.2. Associations between Ki-67 Expressions in CRC Tis-
sues and Clinicopathological Data. The associations observed
between the expression ofKi-67 inCRCand the clinicopatho-
logical data are described in Tables 3 and 4.
Analyzing the results in these tables, we found an associ-
ation between the expression of Ki-67 and “tumour penetra-
tion” (𝑃 = 0.013) and “tumour differentiation” (𝑃 = 0.049).
For “tumour penetration,” we observed a decreasing
expression of Ki-67 from the pT1 (79.3%) to pT3 (68.1%)
tumours and then a rise in expression for adenocarcinoma
with invasion of other organs or structures (pT4) (73.1%).
Regarding “tumour differentiation,” we observed an
increasing expression of Ki-67 from the well-differentiated
to the undifferentiated tumours, namely, well differenti-
ated (64.6%), moderately differentiated (70.2%), and poorly
differentiated (85.1%). Conversely, undifferentiated tumours
showed lower expression of Ki-67 compared to the degree of
differentiation mentioned above.
We did not find any statistically significant relationship
between clinicopathological data and Ki-67 index in CRC for
the remaining assessed data.
3.3. Overall Survival Curves according to Ki-67 Expressions
in CRC Tissues. No statistically significant association was
observed for Ki-67 expression in CRC tissues (𝑃 = 0.321 for
CRC, and𝑃 = 0.213 and𝑃 = 0.874 for colon cancer and rectal
cancer evaluated separately, resp.), as observed in Figure 4.
Relatively to CRC, survival of patients that are negative
for Ki-67 is 65.6% with a medium of survival of 65.0 ± 2.8
months after diagnosis, while Ki-67 positive patients present
a survival of 62.3% with a medium of survival of 62.1 ± 2.1
months after diagnosis, such as is shown in Table 5.
3.4. Ki-67 Expressions in Lymph Node Metastasis Samples. A
total of 210 samples were organized into TMAs. Additionally
35 patients, with the diagnosis of CRC but without lymph
node metastasis, were also selected for control of protein
lymph node expression (stages T1 and T2 N0). Sections were
evaluated for immunoexpression and the obtained results
are given in Table 2, which summarizes the frequency of Ki-
67 expression in “normal” lymph nodes and lymph node
metastasis.
We observed that 55.5% (𝑛 = 60) of the samples of lymph
node metastasis were positive for Ki-67, compared to 100%
(𝑛 = 2) of samples of the samples of “normal” lymph nodes.
No significant correlation was observed (𝑃 = 0.502), such as
is shown in Table 2 and Figure 3.
3.5. Associations between Ki-67 Expressions in Lymph Node
Metastasis and Clinicopathological Data. The associations
observed between the expression of Ki-67 in lymph node
metastasis of CRC and the clinicopathological data are
described in Tables 3 and 4. Analyzing these tables, we
did not find any statistically significant relationship between
clinicopathological data and Ki-67 index in lymph node
metastasis.
3.6. Overall Survival Curves according to Ki-67 Expressions
in Lymph Node Metastasis. Relatively to overall survival,
patients with negative Ki-67 index present a survival of 65.3%
with amediumof survival of 63.4±5.2months after diagnosis,
while Ki-67 index positive patients present a survival of 51.6%
with amediumof survival of 50.0±4.6months after diagnosis,
such as is shown in Table 5.
No statistically significant association was observed for
Ki-67 expression in CRC lymph node metastasis tissues (𝑃 =
0.131 for CRC, 𝑃 = 0.127 and 𝑃 = 0.809 for colon cancer and
rectal cancer evaluated separately, resp.); however, a tendency
for the relationship between a positive Ki-67 index and a
lower overall survival was observed, such as is shown in
Figure 5.
3.7. Comparing Ki-67 Index Expressions in LymphNodeMetas-
tasis and Primary Tumour. Table 6 represents a comparison
between Ki-67 index in the primary tumour and the respec-
tive lymph node metastasis. Analyzing this table, it appears
that 12 of the cases with negative Ki-67 index in the primary
tumour have positive index in lymph node metastasis and
that 29 of those with positive index in the primary tumour
have a negative index in lymph node metastasis, for a total
of 41 discordant cases. This means that there is a significant
difference (𝑃 = 0.012) between the index of Ki-67 in primary
tumour and the respective lymph node metastasis. A smaller
number of cases of positive Ki-67 index were also observed
in lymph nodemetastasis (𝑛 = 61; 57.5%) than in the primary
tumour (𝑛 = 78; 73.6%) as is schematized in Figure 6.
4. Discussion
The mechanisms that culminate in CRC development,
growth, and metastization are still not fully understood.
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Figure 2: Immunohistochemical expression of Ki-67 in colorectal cancer samples: ((a) and (d)) original magnification ×40; ((b) and (e))
original magnification ×100; ((c) and (f)) original magnification ×200.
However, common to all cancers are the loss of cellular
differentiation and the imbalance between proliferation and
cell death; these processes, involved in carcinogenesis, due to
its significance, are increasingly being targeted for study.
Ki-67 protein has beenwidely used as amarker of tumour
proliferation [21, 48, 49], and several studies compare Ki-67
index with clinicopathological data and follow-up in CCR
[22, 32, 35–40]. With regard to Ki-67 index in lymph node
metastasis, as far as we know, this is the first study realized
in CRC and, the more similar that we found in literature
is the study of Yamauchi et al. [41], which compares Ki-67
index in primary CRC tumours with the respective nodules
of peritoneal metastization.
In this study, we determine immunohistochemical
expression of Ki-67 protein in CRC samples and respective
lymph node metastasis and intended to evaluate possible
associations between these expressions and several
clinicopathological parameters and patient survival. Further
comparison was performed between Ki-67 index in CRC
and respective lymph nodes metastasis.
Regarding Ki-67 expression in CRC samples and NAE we
observed a significant expression of Ki-67 in the first over
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Table 3: Assessment of correlation between Ki-67 expression and clinical data.
Ki-67 in CRC Ki-67 in lymph node metastasis
𝑛 Positive 𝑛 (%) 𝑃 𝑛 Positive 𝑛 (%) 𝑃
Gender
Male 307 212 (69.1) 0.675 71 41 (57.7) 0.438
Female 180 121 (67.2) 38 19 (50.0)
Age
≤45 23 14 (60.9) 0.491 7 4 (57.1) 1.000∗
>45 464 319 (68.8) 102 56 (54.9)
Presentation
Asymptomatic 88 63 (71.6) 0.474 19 8 (42.1) 0.212
Symptomatic 399 270 (67.7) 90 52 (57.8)
Localization
Colon 353 240 (68.0) 0.764 90 50 (55.5) 0.841
Rectum 134 93 (69.4) 19 10 (52.6)
Macroscopic cancer type
Polypoid 253 171 (67.6)
0.178
45 20 (44.4)
0.373
Ulcerative 111 76 (68.5) 31 20 (64.5)
Infiltrative 38 22 (57.9) 11 6 (54.5)
Exophytic 39 32 (82.1) 12 7 (58.3)
Vilosous 2 2 (100.0) 1 0 (0)
CEA (ng/mL)
≤10 337 229 (68.0) 0.750 67 34 (50.7) 0.757
>10 73 51 (69.1) 22 12 (54.5)
∗Comparisons were examined for statistical significance using Fisher’s exact test (when 𝑛 < 5).
the second (𝑃 < 0.001). These results were expected, since
due to its role as a marker of cellular proliferation, a higher
expression was expected in tumour tissue than in normal
epithelium. These results were also demonstrated by Lin
et al. [25].
The same analysis was made for lymph nodes metastasis
and “normal” lymph nodes, but no significant correlationwas
observed (𝑃 = 0.502). Possible explanations are the fact that
“normal” lymph nodes are not truly normal, but of patients
with CRC without lymph nodes metastasis (T1 and T2/N0)
so this is a bias to be considered since they may already be
under the influence of the tumour environment. Another fact
that may influence this result is the small size sample of the
“normal” lymph node, so further studies need to be realized
with bigger samples and normal lymph nodes for control.
When analyzing the correlation of Ki-67 expression in
CRCwith pathological data, we found an association between
the expression ofKi-67 and “tumour penetration” (𝑃 = 0.013)
and “tumour differentiation” (𝑃 = 0.049).
For “tumour penetration,” we observed a decreasing
expression of Ki-67 from the pT1 (79.3%) to pT3 (68.1%)
tumours and then a rise in expression for adenocarcinoma
with invasion of other organs or structures (pT4) (73.1%).
The decreased expression of Ki-67 with the increasing
tumour penetration is conflicting since we would expect an
increase in expression with increasing tumour wall pene-
tration, as is observed for pT4. But as the Ki-67 is only a
marker of cellular proliferation, other factors may influence
this outcome.
Regarding “tumour differentiation,” we observed an
increasing expression of Ki-67 from the well-differentiated
to the undifferentiated tumours; conversely, undifferentiated
tumours showed lower expression of Ki-67 compared to the
degree of differentiation mentioned above.
As was observed by some authors [38, 50], the more
undifferentiated is the tumour, the higher is the rate of cell
proliferation and therefore Ki-67 index.This is not consistent
with our findings; however, since the lower expression in
undifferentiated tumours may be explained by the small
size of this sample, further studies with larger series of
undifferentiated tumours are necessary.
When analyzing the correlation of Ki-67 expression in
lymph node metastasis with pathological data, any statisti-
cally significant relationship was observed. In the literature,
no other studies realized in lymph node metastasis of CRC
were found, and similar results were observed by Jansson and
Sun [39] on the primary tumour but contradict the other
studies analyzed [22, 25, 28–30, 32, 35–40].
In our series, we have not observed association between
Ki-67 expression and patient’s survival, for CRC (𝑃 = 0.321)
and for lymph node metastasis (𝑃 = 0.131), series and the
same was true when we considered separately colon cancer
and rectal cancer. This was corroborated by the observations
of Jansson and Sun [39]; however, these findings contradict,
in part, the report of Valera et al. [35] that studied primary
CRC tumours, and also contradict studies made with lymph
node metastasis from breast cancer [43–45] and prostate
BioMed Research International 7
Table 4: Assessment of correlation between Ki-67 expression and pathological data.
Ki-67 in CRC Ki-67 in lymph node metastasis
𝑛 Positive 𝑛 (%) 𝑃 𝑛 Positive 𝑛 (%) 𝑃
Tumor size
≤4.5 cm 279 190 (68.1) 0.519 65 39 (60.0) 0.211
>4.5 cm 179 127 (70.9) 40 19 (47.5)
Histological type
Adenocarcinoma 409 281 (68.7)
0.665
88 46 (52.3)
0.483Mucinous adenocarcinoma 50 32 (64.0) 13 8 (61.5)
Invasive adenocarcinoma 24 18 (75.0) 6 4 (66.7)
Signet ring and mucinous 4 2 (50.0) 2 2 (100.0)
Differentiation
Well differentiated 209 135 (64.6)
0.049
38 19 (50.0)
0.670Moderately differentiated 208 146 (70.2) 46 26 (56.5)
Poorly differentiated 47 40 (85.1) 23 14 (60.9)
Undifferentiated 4 3 (75.0) 1 1 (100.0)
Tumour penetration
pT1 34 23 (79.3)
0.013
2 2 (100.0)
0.553pT2 57 39 (68.4) 4 2 (50.0)
pT3 370 252 (68.1) 96 53 (55.2)
pT4 26 19 (73.1) 7 3 (42.9)
Spread to lymph nodes
Absent 275 188 (68.4) 0.940 9 5 (55.6) 1.000∗
Present 198 136 (68.7) 89 50 (56.2)
Venous vessel invasion
Absent 264 179 (67.8) 0.511 29 13 (44.8) 0.110
Present 201 142 (70.4) 74 46 (62.2)
TNM
Stage I 75 54 (72.0)
0.425Stage II 181 121 (66.9)
Stage III 152 108 (71.1) 78 43 (55.1) 0.978
Stage IV 70 45 (64.3) 31 17 (54.8)
∗Comparisons were examined for statistical significance using Fisher’s exact test (when 𝑛 ≤ 5).
Table 5: Survival analysis: frequency and relative frequency for overall survival and medium of time to death.
Ki-67 Tissue 𝑛 Deaths
𝑛 (%)
Median for survival time
[95% confidence interval] Log-rank test 𝑃
Negative CRC 154 53 (65.6) 65.00 [59.49–70.52] 0.321
Positive 332 125 (62.3) 62.09 [58.06–66.12]
Negative Lymph node 49 17 (65.3) 63.48 [53.18–73.79] 0.131
Positive 62 30 (51.6) 50.07 [41.06–59.08]
Table 6: Comparison between Ki-67 index in primary tumor and respective lymph node metastasis.
Ki-67 index in CRC Ki-67 index in lymph node
Negative Positive Total 𝑛 (%)
Negative 16 12 28 (26.4)
Positive 29 49 78 (73.6)
Total 𝑛 (%) 45 (42.5) 51 (57.5) 106 (100)
Comparisons were examined for statistical significance using McNemar test.
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Figure 3: Immunohistochemical expression of Ki-67 in CRC lymph node metastasis samples: ((a) and (d)) original magnification ×40; ((b)
and (e)) original magnification ×100; ((c) and (f)) original magnification ×200.
cancer [51], where a higher ki-67 index was associated with
a worse patient survival.
Finally, we found association (𝑃 = 0.012) between Ki-
67 index in primary tumour and the respective lymph node
metastasis and also observed that Ki-67 index was more
often positive in the primary tumour than in the respective
lymph node metastasis. This result is consistent with the
study carried out by Yamauchi et al. [41] to compare Ki-
67 index in CRC primary tumour and respective nodules
of peritoneal dissemination, which, as in the present study,
present a greater proportion of proliferating cells in the
primary tumour than in the nodules of peritoneal dissem-
ination, not advancing; however, there is no explanation
for this finding. Distinct results were observed for similar
studies realized in breast cancer [42–44], where lymph node
metastasis presents higher ki-67 index than primary tumour,
but also no explanation was mentioned. Recently, Jo and
colleagues have found a significant difference of higher Ki-67
proliferation in nodal metastasis and primary gastric cancer
[52]. Most of the criticism of Ki-67 evaluation is related
to the differences of antibodies, slide background, retrieval
protocols applied in preparing the immunoreaction, and the
scores used to evaluate the significance of Ki-67 proliferation
rates. This concern is pertinent and most of the works that
evaluate this premise did not reach a consensus. Interesting,
automated evaluation of the Ki-67 labelled preparation has
been adjudicated as superior than manual analyses. More-
over, subdividing the cases in low and high proliferative rate
improve the kappa correlation. Besides these advisements,
the lack of standard protocols among the laboratories limits
the clinical relevance of the works [53].
This difference between Ki-67 index in primary CRC
tumour and respective lymph node metastasis may explain
the absence of correlation with clinicopathological data
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Figure 4: Survival curve of patients with CRC according to Ki-67, assessed by the log-rank test: (a) colorectal cancer: 𝑃 = 0.321; (b) colon
cancer: 𝑃 = 0.213; (c) rectal cancer: 𝑃 = 0.874.
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Figure 5: Survival curve of patients with CRC lymph node metastasis according to Ki-67, assessed by the log-rank test: (a) colorectal cancer:
𝑃 = 0.131; (b) colon cancer: 𝑃 = 0.127; (c) rectal cancer: 𝑃 = 0.809.
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Figure 6: Graphic representation of Ki-67 index in primary CRC
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and survival observed in this study as it shows that the
proliferative profile of the primary CRC tumour is different
from that of its metastasis. One possible explanation for
the low proliferative index of lymph node metastasis as
compared to primary tumour is that lymph node cannot
represent an optimal proliferative environment, since it is
known that nutrient and oxygen deprivation induces cell
cycle arrest, leading to a decreased proliferation rate [54].
Another possible explanation may be due to of Ki-67 own
usage as a marker of cell proliferation, since Ki-67 expression
seems to be influenced by nutrient intake of the cell [48].
The smaller number of patients with a positive Ki-67
index in lymph node metastasis can also contribute to the
poor prognosis attributed to the presence of lymph node
metastasis [32, 50, 55, 56] in CCR, since most antineoplastic
agents target proliferating cells, cells with a low proliferation
rate are more resistant to such treatment [53], and this
hypothesis was also stated by Cabibi et al. [44], relatively to
the subgroup of patients with breast cancer and lower ki-67
index in lymph node metastasis than in primary tumour.
5. Conclusions
In this study, we evaluated the immunohistochemical expres-
sion of Ki-67 in CRC and respective lymph node metastasis
and simultaneously try to determine its correlation with
clinicopathological data andpatient survival. From the results
obtained, it was found that this protein has higher expression
in tumour tissue, supporting the hypothesis of involvement
of Ki-67 in CRC and its role as a proliferative marker.
Furthermore, in CRC samples, the association between the
expression of this protein and the degree of tumour differen-
tiation and penetration was found which enables Ki-67 to be
used as a potential prognostic factor in CRC.
Although we have not obtained statistical significant
results for lymph node metastasis series we observed a
statistically significant difference between the Ki-67 index
of the primary tumour and the respective lymph node
metastasis, which is more often positive in the primary
tumour. These results show that lymph node metastasis is
composed of proliferating cells slower than that present in the
primary tumour and it is hypothesized that the lymph node
might not constitute an optimal environment for tumour cells
proliferation or that Ki-67 might not be the more suitable
proliferative marker for use in lymph node metastasis. This
result also raises the possibility that tumour cells in lymph
nodes can be more resistant to chemotherapy treatments,
thus contributing to the poor prognosis of these patients.
Conflict of Interests
The authors declare that they have no conflict of interests.
References
[1] S. Svagzdys, V. Lesauskaite, D. Pavalkis, I. Nedzelskiene, D.
Pranys, and A. Tamelis, “Microvessel density as new prognostic
marker after radiotherapy in rectal cancer,” BMC Cancer, vol. 9,
article 95, 2009.
[2] G. Des Guetz, B. Uzzan, P. Nicolas et al., “Microvessel density
and VEGF expression are prognostic factors in colorectal
cancer.Meta-analysis of the literature,”British Journal of Cancer,
vol. 94, no. 12, pp. 1823–1832, 2006.
[3] H. Brenner, M. Hoffmeister, and U. Haug, “Should colorectal
cancer screening start at the same age in European countries?
Contributions from descriptive epidemiology,” British Journal
of Cancer, vol. 99, no. 3, pp. 532–535, 2008.
[4] S. F. Martins, R. M. Reis, A. M. Rodrigues, F. Baltazar, and A.
Filho, “Role of endoglin and VEGF family expression in col-
orectal cancer prognosis and anti-angiogenic therapies,”World
Journal of Clinical Oncology, vol. 2, no. 6, pp. 272–280, 2011.
[5] S. F. Martins, E. A. Garcia, M. A. M. Luz, F. Pardal, M.
Rodrigues, andA. L. Filho, “Clinicopathological correlation and
prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and
VEGFR-3 expression in colorectal cancer,” Cancer Genomics &
Proteomics, vol. 10, no. 2, pp. 55–67, 2013.
[6] M. Zavoral, S. Suchanek, F. Zavada et al., “Colorectal cancer
screening in Europe,”World Journal of Gastroenterology, vol. 15,
no. 47, pp. 5907–5915, 2009.
[7] C. Bosetti, F. Levi, V. Rosato et al., “Recent trends in colorectal
cancermortality in Europe,” International Journal of Cancer, vol.
129, no. 1, pp. 180–191, 2011.
[8] Roreno, Corpo Humano—Roreno—Registo Oncolo´gico Re-
gional do Norte, http://www.roreno.com.pt/p.
[9] M. Malvezzi, P. Bertuccio, F. Levi, C. La Vecchia, and E. Negri,
“European cancer mortality predictions for the year 2013,”
Annals of Oncology, vol. 24, no. 3, pp. 792–800, 2013.
[10] C. G. Pinto, A. T. Paquete, and I. Pissarra, “Colorectal cancer in
Portugal,” European Journal of Health Economics, vol. 10, no. 1,
pp. S65–S73, 2010.
[11] J. Ferlay, E. Steliarova-Foucher, J. Lortet-Tieulent et al., “Cancer
incidence and mortality patterns in Europe: estimates for 40
countries in 2012,” European Journal of Cancer, vol. 49, no. 6,
pp. 1374–1403, 2013.
[12] S. Gurzu, J. Jung, L. Azamfirei, T. Mezei, A. M. Cıˆmpean,
and Z. Szentirmay, “The angiogenesis in colorectal carcinomas
with and without lymph nodemetastases,” Romanian Journal of
Morphology and Embryology, vol. 49, no. 2, pp. 149–152, 2008.
12 BioMed Research International
[13] S. Cascinu, V. Georgoulias, D. Kerr, T. Maughan, R. Labianca,
and M. Ychou, “Colorectal cancer in the adjuvant setting:
perspectives on treatment and the role of prognostic factors,”
Annals of Oncology, vol. 14, no. 2, pp. 25–29, 2003.
[14] D. D. Alexander, J. Waterbor, T. Hughes, E. Funkhouser, W.
Grizzle, and U. Manne, “African-American and Caucasian
disparities in colorectal cancer mortality and survival by data
source: an epidemiologic review,” Cancer Biomarkers, vol. 3, no.
6, pp. 301–313, 2007.
[15] H. J. Calvo, G. D. Ortega, R. J. M. Pardo, M. A. J. Lo´pez, and T.
Cubo, “Biologia molecular del processo metasta´sico del cancer
colorectal,” Cirugia Espan˜ola, vol. 68, pp. 577–587, 2000.
[16] S. Y. Zafar, A. P. Abernethy, D. H. Abbott et al., “Comorbidity,
age, race and stage at diagnosis in colorectal cancer: a retrospec-
tive, parallel analysis of two health systems,” BMC Cancer, vol.
8, article 345, 2008.
[17] L. A. G. Ries, P. A. Wingo, D. S. Miller et al., “The annual report
to the nation on the status of cancer, 1973–1997, with a special
section on colorectal cancer,” Cancer, vol. 88, no. 10, pp. 2398–
2424, 2000.
[18] R. S. Saad, Y. L. Liu, G.Nathan, J. Celebrezze,D.Medich, and J. F.
Silverman, “Endoglin (CD105) and vascular endothelial growth
factor as prognostic markers in colorectal cancer,” Modern
Pathology, vol. 17, no. 2, pp. 197–203, 2004.
[19] C. Barozzi,M. Ravaioli, A. D’Errico et al., “Relevance of biologic
markers in colorectal carcinoma: a comparative study of a broad
panel,” Cancer, vol. 94, no. 3, pp. 647–657, 2002.
[20] A. J. Bilchik,M.DiNome, S. Saha et al., “Prospectivemulticenter
trial of staging adequacy in colon cancer: preliminary results,”
Archives of Surgery, vol. 141, no. 6, pp. 527–533, 2006.
[21] T. Scholzen and J. Gerdes, “The Ki-67 protein: from the known
and the unknown,” Journal of Cellular Physiology, vol. 182, no. 3,
pp. 311–322, 2000.
[22] K. Guzinska-Ustymowicz, E. Stepien, and A. Kemona, “MCM-
2, Ki-67 and PCNA protein expressions in pT3G2 colorec-
tal cancer indicated lymph node involvement,” Anticancer
Research, vol. 28, no. 1, pp. 451–457, 2008.
[23] D. Freitas, M. H. Goula˜o, E. Camacho et al., “Clinical relevance
of proliferation biomarkers and p53 expression in rectal mucosa
and sporadic colonic adenomas: a prospective study,” Hepato-
Gastroenterology, vol. 49, no. 47, pp. 1269–1274, 2002.
[24] H. A. Saleh, H. Jackson, G. Khatib, and M. Banerjee, “Corre-
lation of bcl-2 oncoprotein immunohistochemical expression
with proliferation index and histopathologic parameters in
colorectal neoplasia,” Pathology &Oncology Research, vol. 5, no.
4, pp. 273–279, 1999.
[25] M. X. Lin, Z.-F. Wen, Z.-Y. Feng, and D. He, “Expression and
significance of Bmi-1 and Ki67 in colorectal carcinoma tissues,”
Ai Zheng, vol. 27, no. 12, pp. 1321–1326, 2008.
[26] P. Dziegiel, J. Forgacz, E. Suder, P. Surowiak, J. Kornafel, and M.
Zabel, “Prognostic significance of metallothionein expression
in correlation with Ki-67 expression in adenocarcinomas of
large intestine,” Histology and Histopathology, vol. 18, no. 2, pp.
401–407, 2003.
[27] X. Z. Bai, J. R. W. Masters, N. O’Donoghue et al., “Prognostic
markers in clinically localised prostate cancer,” International
Journal of Oncology, vol. 14, no. 4, pp. 785–791, 1999.
[28] W. X. Gao, J. G. Feng, Y. F. Yang et al., “PCNA in colorectal
carcinoma and the prognosis,” Xian Dai Yu Fang Yi Xue, vol.
2, no. 34, pp. 225–229, 2007.
[29] M.Micev, M.Micev-Cosic´, V. Todorovic´ et al., “Histopathology
of residual rectal carcinoma following preoperative radiochem-
otherapy,” Acta Chirurgica Iugoslavica, vol. 51, no. 2, pp. 99–108,
2004.
[30] F. L. Nussrat, H. H. Ali, H. G. Hussein, and R. J. Al-Ukashi,
“Immunohistochemical expression of ki-67 and p53 in col-
orectal adenomas: a clinicopathological study,” Oman Medical
Journal, vol. 26, no. 4, pp. 229–234, 2011.
[31] S. Toru and B. Bilezikc¸i, “Early changes in carcinogenesis of
colorectal adenomas,” West Indian Medical Journal, vol. 61, no.
1, pp. 10–16, 2012.
[32] Y.Hashimoto,M. Skacel, I. C. Lavery, A. L.Mukherjee,G.Casey,
and J. C. Adams, “Prognostic significance of fascin expression in
advanced colorectal cancer: an immunohistochemical study of
colorectal adenomas and adenocarcinomas,” BMC Cancer, vol.
6, article 241, 2006.
[33] C. T. F. Oshima, K. Iriya, and N. M. Forones, “Ki-67 as
a prognostic marker in colorectal cancer but not in gastric
cancer,” Neoplasma, vol. 52, no. 5, pp. 420–424, 2005.
[34] C. Evans, I. Morrison, A. G. Heriot et al., “The correlation
between colorectal cancer rates of proliferation and apoptosis
and systemic levels plus their influence upon survival,” British
Journal of Cancer, vol. 94, no. 10, pp. 1412–1419, 2006.
[35] V. Valera, N. Yokoyama, B.Walter, H. Okamoto, T. Suda, and K.
Hatakeyama, “Clinical significance of Ki-67 proliferation index
in disease progression and prognosis of patients with resected
colorectal carcinoma,” British Journal of Surgery, vol. 92, no. 8,
pp. 1002–1007, 2005.
[36] H. L. De Menezes, M. J. Juca´, E. G. D. A. Gomes, B. L. B.
B. P. Nunes, H. O. Costa, and D. Matos, “Analysis of the
immunohistochemical expressions of p53, bcl-2 and Ki-67
in colorectal adenocarcinoma and their correlations with the
prognostic factors,” Arquivos de Gastroenterologia, vol. 47, no.
2, pp. 141–147, 2010.
[37] C. Ghit¸a˘, I. D. Vıˆlcea, M. Dumitrescu et al., “The prognostic
value of the immunohistochemical aspects of tumor suppressor
genes p53, bcl-2, PTEN and nuclear proliferative antigen Ki-
67 in resected colorectal carcinoma,” Romanian Journal of
Morphology and Embryology, vol. 53, no. 3, pp. 549–556, 2012.
[38] U. Nabi, A. H. Nagi, and W. Sami, “Ki-67 proliferating index
and histological grade, type and stage of colorectal carcinoma,”
Journal of Ayub Medical College, Abbottabad, vol. 20, no. 4, pp.
44–48, 2008.
[39] A. Jansson and X.-F. Sun, “Ki-67 expression in relation to
clinicopathological variables and prognosis in colorectal ade-
nocarcinomas,” APMIS, vol. 105, no. 9, pp. 730–734, 1997.
[40] C. J. Allegra, S. Paik, L. H. Colangelo et al., “Prognostic value
of thymidylate synthase, Ki-67, and p53 in patients with Dukes’
B and C colon cancer: a National Cancer Institute-National
Surgical Adjuvant Breast andBowel Project collaborative study,”
Journal of Clinical Oncology, vol. 21, no. 2, pp. 241–250, 2003.
[41] H. Yamauchi, T. Suto, W. Kigure et al., “The progression poten-
tial of peritoneal dissemination nodules from gastrointestinal
tumors,” International Surgery, vol. 96, no. 4, pp. 352–357, 2011.
[42] F. Buxant, V. Anaf, P. Simon, I. Fayt, and J. C. Noe¨l, “Ki-67
immunostaining activity is higher in positive axillary lymph
nodes than in the primary breast tumor,”Breast Cancer Research
and Treatment, vol. 75, no. 1, pp. 1–3, 2002.
[43] D. Park, R. Ka˚resen, T. Noren, and T. Sauer, “Ki-67 expression
in primary breast carcinomas and their axillary lymph node
metastases: clinical implications,” Virchows Archiv, vol. 451, no.
1, pp. 11–18, 2007.
BioMed Research International 13
[44] D. Cabibi, V. Mustacchio, A. Martorana et al., “Lymph node
metastases displaying lower Ki-67 immunostaining activity
than the primary breast cancer,” Anticancer Research, vol. 26,
no. 6B, pp. 4357–4360, 2006.
[45] K. Tawfik, B. F. Kimler, M. K. Davis, F. Fan, and O. Tawfik,
“Ki-67 expression in axillary lymph node metastases in breast
cancer is prognostically significant,” Human Pathology, vol. 44,
no. 1, pp. 39–46, 2013.
[46] F. L. Greene, D. L. Page, I. D. Fleming et al., Eds., AJCC Cancer
Staging Manual, Springer, New York, NY, USA, 6th edition,
2002.
[47] C. Pinheiro, A. Longatto-Filho, C. Scapulatempo et al., “In-
creased expression of monocarboxylate transporters 1, 2, and 4
in colorectal carcinomas,” Virchows Archiv, vol. 452, no. 2, pp.
139–146, 2008.
[48] D. C. Brown and K. C. Gatter, “Monoclonal antibody Ki-67: its
use in histopathology,” Histopathology, vol. 17, no. 6, pp. 489–
503, 1990.
[49] J. Gerdes, U. Schwab, H. Lemke, and H. Stein, “Production of
a mouse monoclonal antibody reactive with a human nuclear
antigen associated with cell proliferation,” International Journal
of Cancer, vol. 31, no. 1, pp. 13–20, 1983.
[50] Y. Kubota, R. E. Petras, K. A. Easley, T. W. Bauer, R. R.
Tubbs, and V. W. Fazio, “Ki-67-determined growth fraction
versus standard staging and grading parameters in colorectal
carcinoma: a multivariate analysis,” Cancer, vol. 70, no. 11, pp.
2602–2609, 1992.
[51] M.Hosaka, Y. Takano,M. Iki, and et al, “Prognostic significance
of Ki-67, p53, and Bcl-2 expression in prostate cancer patients
with lymph node metastases: a retrospective immunohisto-
chemical analysis,” Pathology International, vol. 48, no. 1, pp. 41–
46, 1998.
[52] M. J. Jo, J. Y. Park, J. S. Song et al., “Biopathologic features and
clinical significance of micrometatasis in the lymph node of
early gastric cancer,”World Journal of Gastroenterology, vol. 21,
no. 2, pp. 667–674, 2015.
[53] J. Harvey, C. Thomas, B. Wood et al., “Practical issues concern-
ing the implementation of Ki-67 proliferative index measure-
ment in breast cancer reporting,” Pathology, vol. 47, no. 1, pp.
13–20, 2015.
[54] O. Tre´dan, C. M. Galmarini, K. Patel, and I. F. Tannock, “Drug
resistance and the solid tumor microenvironment,” Journal of
the National Cancer Institute, vol. 99, no. 19, pp. 1441–1454, 2007.
[55] D. L. Longo, A. S. Fauci, D. L. Kasper, S. L. Hauser, J. L. Jameson,
and J. Loscalzo, Eds., Harrison’s Principles of Internal Medicine,
McGraw-Hill, New York, NY, USA, 18th edition, 2012.
[56] T. E. Le Voyer, E. R. Sigurdson, A. L. Hanlon et al., “Colon
cancer survival is associated with increasing number of lymph
nodes analyzed: a secondary survey of intergroup trial INT-
0089,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2912–2919,
2003.
